image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 34.94
-0.143 %
$ 1.73 B
Market Cap
-43.05
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 7, 2025.

The intrinsic value of one ATRC stock under the worst case scenario is HIDDEN Compared to the current market price of 34.9 USD, AtriCure, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 7, 2025.

The intrinsic value of one ATRC stock under the base case scenario is HIDDEN Compared to the current market price of 34.9 USD, AtriCure, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 7, 2025.

The intrinsic value of one ATRC stock under the best case scenario is HIDDEN Compared to the current market price of 34.9 USD, AtriCure, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ATRC

image
$44.0$44.0$42.0$42.0$40.0$40.0$38.0$38.0$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
465 M REVENUE
16.55%
-40 M OPERATING INCOME
-49.96%
-44.7 M NET INCOME
100.00%
12.2 M OPERATING CASH FLOW
172.17%
30.2 M INVESTING CASH FLOW
38.58%
-3.6 M FINANCING CASH FLOW
-11159.38%
124 M REVENUE
-0.53%
-5.95 M OPERATING INCOME
59.00%
-6.75 M NET INCOME
56.66%
-11 M OPERATING CASH FLOW
-188.93%
-1.68 M INVESTING CASH FLOW
88.56%
-10.3 M FINANCING CASH FLOW
-594.07%
Balance Sheet AtriCure, Inc.
image
Current Assets 268 M
Cash & Short-Term Investments 123 M
Receivables 60.3 M
Other Current Assets 84.8 M
Non-Current Assets 342 M
Long-Term Investments 0
PP&E 47.4 M
Other Non-Current Assets 294 M
20.14 %9.90 %13.91 %7.78 %48.27 %Total Assets$609.3m
Current Liabilities 73.4 M
Accounts Payable 25 M
Short-Term Debt 2.8 M
Other Current Liabilities 45.6 M
Non-Current Liabilities 74.9 M
Long-Term Debt 61.9 M
Other Non-Current Liabilities 13.1 M
16.87 %30.73 %41.70 %8.81 %Total Liabilities$148.4m
EFFICIENCY
Earnings Waterfall AtriCure, Inc.
image
Revenue 465 M
Cost Of Revenue 118 M
Gross Profit 348 M
Operating Expenses 388 M
Operating Income -40 M
Other Expenses 4.68 M
Net Income -44.7 M
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)465m(118m)348m(388m)(40m)(5m)(45m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
74.69% GROSS MARGIN
74.69%
-8.60% OPERATING MARGIN
-8.60%
-9.61% NET MARGIN
-9.61%
-9.70% ROE
-9.70%
-7.34% ROA
-7.34%
-7.60% ROIC
-7.60%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AtriCure, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -44.7 M
Depreciation & Amortization 18.7 M
Capital Expenditures -23.5 M
Stock-Based Compensation 0
Change in Working Capital 0
Others 12.2 M
Free Cash Flow -11.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AtriCure, Inc.
image
Wall Street analysts predict an average 1-year price target for ATRC of $39.7 , with forecasts ranging from a low of $26 to a high of $53 .
ATRC Lowest Price Target Wall Street Target
26 USD -25.59%
ATRC Average Price Target Wall Street Target
39.7 USD 13.53%
ATRC Highest Price Target Wall Street Target
53 USD 51.69%
Price
Max Price Target
Min Price Target
Average Price Target
55555050454540403535303025252020Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership AtriCure, Inc.
image
Sold
0-3 MONTHS
83.6 K USD 1
3-6 MONTHS
233 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
84.2 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. AtriCure's management is scheduled to host a fireside chat on Monday, June 9, 2025, at 4:00 p.m. Eastern Standard Time. Interested parties may acc. businesswire.com - 3 weeks ago
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect? The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Matthew O'Brien - Piper Sandler Companies John McAulay - Stifel Financial Corp. Lily Lozada - JPMorgan Chase & Co. Marie Thibault - BTIG, LLC Danny Stauder - Citizens JMP Securities, LLC Mike Matson - Needham & Company, LLC Danielle Antalffy - UBS Group AG Suraj Kalia - Oppenheimer & Co. Inc. Operator Good afternoon, and welcome to AtriCure's First Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes. seekingalpha.com - 1 month ago
AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates AtriCure (ATRC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago. zacks.com - 1 month ago
AtriCure Reports First Quarter 2025 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. “Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “As. businesswire.com - 1 month ago
AtriCure to Announce First Quarter 2025 Financial Results MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, April 29, 2025, to discuss its first quarter 2025 financial results. Those interested in list. businesswire.com - 2 months ago
AtriCure to Host Analyst & Investor Day on March 26, 2025 MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expa. businesswire.com - 3 months ago
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 4 months ago
AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes. seekingalpha.com - 4 months ago
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 4 months ago
AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates AtriCure (ATRC) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.21 per share a year ago. zacks.com - 4 months ago
8. Profile Summary

AtriCure, Inc. ATRC

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 1.73 B
Dividend Yield 0.00%
Description AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Contact 7555 Innovation Way, Mason, OH, 45040 https://www.atricure.com
IPO Date Aug. 5, 2005
Employees 1300
Officers Mr. Salvatore Privitera J.D. Chief Technical Officer Ms. Angela L. Wirick Chief Financial Officer Mr. Justin J. Noznesky Chief Marketing & Strategy Officer Mr. Michael H. Carrel Chief Executive Officer, President & Director Mr. Douglas J. Seith Chief Operating Officer Mr. Karl S. Dahlquist CCEP, J.D. Chief Legal Officer Dr. Vinayak Doraiswamy Ph.D. Chief Scientific Officer Valerie Storch-Willhaus Vice President of Corporate Marketing & Communications